Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01809782
Other study ID # Two-stage liver
Secondary ID
Status Terminated
Phase N/A
First received February 26, 2013
Last updated January 16, 2018
Start date March 11, 2013
Est. completion date August 10, 2017

Study information

Verified date January 2018
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cognitive outcome (delirium and post-operative cognitive deficiency) in patients undergoing two-time liver resection.


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date August 10, 2017
Est. primary completion date April 16, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Study Group:

Inclusion Criteria:

- Patients undergoing a planned elective in situ split liver operation with following resection after approximately ten days with or without additional elective surgery in the same session at the University Hospital, Campus Virchow-Klinikum of the Charité - University Medicine Berlin

- Patients aged greater than or equal to 18 years

- Patients of both genders

- Offered patient information and written informed consent

- No participation in another clinical trial according to the German Drug Law (AMG) during the trial and one month before inclusion

Exclusion Criteria:

- Lacking willingness to save and hand out pseudonymised data within the clinical study

- Accommodation in an institution due to an official or judicial order

- Staff of Charite University hospital Berlin, Virchow Klinikum

- Illiteracy

- Unability of German language use

- Visual and acoustical impairment

- core on the mini mental state examination (MMSE) at screening of 23 or less

- American Society of Anaesthesiologists (ASA) Classification greater than IV

- Ascertained psychiatric disease

- Intake of psychotropic drugs (including sleeping pills and Benzodiazepine)

- Symptomatic bradycardia

- Symptomatic heart rhythm disorder (arrhythmia)

- Coronary heart disease Canadian Society of Anaesthesiologists criteria (CSC) stadium IV or the presentation of a coronary heart disease that needs intervention

Control Group:

Inclusion criteria:

•Male and female ASA II/III patients, aged = 18 years

Exclusion Criteria:

- Mini-Mental-State-Examination = 23 Points

- Neuropsychiatric morbidity, which limits the conduction of the neurocognitive testing

- Taking psychothropic drugs (including sleep-inducing drug and benzodiazepine) on a regular basis

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte and Campus Virchow-Klinikum Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary POCD Measured by Cambridge Neurophysiological Test Automated Battery (CANTAB); calculated in relation to a healthy control group without intervention At postoperative day 7 after second liver operation
Primary Delirium Measured by Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) At postoperative day 7 after second liver operation
Secondary Delirium Measured by Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and Confusion Assessment Method (CAM) and Intensive Care Delirium Screening Checklist (ICDSC) and Delirium Detection Scale (DDS) and Delirium Rating Scale (DRS) and The Nursing Delirium Screening Scale (NU-DESC) At postoperative day 7 after second liver operation
Secondary Change of POCD Measured by Cambridge Neurophysiological Test Automated Battery (CANTAB) calculated in relation to a healthy control group without intervention Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Simplifies Acute Physiology Score (SAPS II) Simplifies Acute Physiology Score (SAPS II) At postoperative day 7 after second liver operation
Secondary Length of post-operative hospital stay Post-anaesthesia Discharge Scoring Stay (PADSS) Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary Length of post-operative intensive care unit stay Criteria of internal standard operating procedures (SOP) Participants will be followed for the duration of hospital stay, an expected average of 3 weeks
Secondary Pain Measured by Numeric Rating Scale (NRS) or Verbal Rating Scale (VRS) or Visual Analogue Scale (VAS) or Behavioural Pain Scale (BPS) Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary The rate of post-operative organ dysfunctions and complications Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary Incidence of systemic inflammatory response syndrome (SIRS) and infection Centers for Disease Control (CDC) and American Thoracic Society (ATS) criteria Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary Change of 36-item short form health survey (SF-36) 36-item short form health survey (SF-36) Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Mortality postoperative survival after 90 days, after 182 days and after 365 days
Secondary Acute Physiological and Chronic Health Evaluation (Apache II) Acute Physiological and Chronic Health Evaluation (Apache II) At postoperative day 7 after second liver operation
Secondary Sequental Organ Failure Assessment (SOFA) Sequental Organ Failure Assessment (SOFA) At postoperative day 7 after second liver operation
Secondary TISS Therapeutic Interventions Scoring System (TISS) At postoperative day 7 after second liver operation
Secondary RASS Richmonds Agitation Sedations Scale (RASS) At postoperative day 7 after second liver operation
Secondary GCS Glasgow Coma Scale (GCS) At postoperative day 7 after second liver operation
Secondary RIFLE criteria Risk Injury Failure Loss End Stage Kidney Disease (RIFLE = risk (R), injury (I), and failure (F), sustained loss (L) and end-stage kidney disease (E)) At postoperative day 7 after second liver operation
Secondary Change of EuroQoL instrument (EQ-5D) EuroQoL instrument (EQ-5D) Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Change of Barthel Index(for Activities of Daily Living, ADL) Barthel Index (for Activities of Daily Living, ADL) Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Change of Instrumentelle Aktivität im täglichen Leben (IATL) Instrumentelle Aktivität im täglichen Leben (IATL) Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Change of Geriatric Depression Scale (GDS) Geriatric Depression Scale (GDS) Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Change of Cornell Depression Scale (CDS) Cornell Depression Scale (CDS) Change from pre-operative (Baseline) up to 365 days after surgery
Secondary Change of Hospital Anxiety and Depression Scale deutsche Version (HADS-D) Hospital Anxiety and Depression Scale deutsche Version (HADS-D) Change from pre-operative (Baseline) up to 365 days after surgery